

REMARKS

The Applicants are requesting the entry of an amendment to the Specification which added the priority claim. No new matter is being added.

The Applicant request entry of the amendment to the Abstract to include the definitions of Claim 1 into the Abstract, thus bringing it in line with U.S. practice. No new matter is being added.

The Applicants request entry of amendments to Claims 3-22, and 24-26. The amendments to Claims 3-22 removes the multiple dependency for these claims. The amendments to Claims 24-26 help make these claims read better and better comply with US practice.

The Applicants request the cancellation of Claims 27-30.

The Applicants request the entry of new Claims 31-41. New Claims 31-41 are based on cancelled Claims 27-30 but are in language appropriate for US practice. Support for Claims 31-41 can be found on pages 8-13 and 26-31.

No new matter is being added.


Applicants authorizes the Commissioner to charge all fees due to Deposit Account 19-0134. Applicants also requests that all correspondence be directed to the address associated with Customer Number 001095 which is currently as follows:

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080

Any questions or issues can be directed to the below signed attorney at this address.
Thank you for your assistance with this matter.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7922



David L. Marks
Attorney for Applicants
Reg. No. 37,881

Date: June 1, 2006